Low Libido With PCOS: Why High Testosterone Does Not Fix It

Does PCOS actually lower sex drive, or is the evidence mixed?

Both are true, and the honest answer depends on which study and which measure. The largest and most recent meta-analysis — 40 studies, using the Female Sexual Function Index (FSFI) — found women with PCOS scored significantly lower across every single domain measured: desire, arousal, lubrication, orgasm, satisfaction, and pain, with the desire domain showing a standardised mean difference of -0.22 (Bachega et al., 2025). An earlier and smaller meta-analysis of 10 studies, by contrast, found no significant difference in overall risk of sexual dysfunction (RR 1.09, 95% CI 0.90–1.32) (Zhao et al., 2019). The discrepancy is mostly about scale and measurement consistency — the 2025 analysis pooled far more data using one validated tool. Where both agree: PCOS does not raise sex drive, and the studies that find a difference all find it pointing the same direction, downward.

Why doesn’t higher testosterone mean higher libido?

Because androgen level and sexual desire aren’t the same lever in women, and in PCOS specifically the correlation runs backward from what the “high testosterone, high sex drive” assumption predicts. In a controlled study of 64 sexually active women, total FSFI score correlated negatively with both total testosterone (r = -0.28) and free testosterone (r = -0.49) — the higher a woman’s free testosterone, the lower her measured sexual function, not the higher (Ercan et al., 2013). Free testosterone is the relevant number, not total, because most circulating testosterone is bound to sex hormone binding globulin (SHBG) and biologically inactive; PCOS commonly lowers SHBG, which raises the free fraction even when total testosterone looks unremarkable — a distinction covered in full in what counts as high testosterone in women, and what’s behind it. Desire in women is driven by a mix of central nervous system, relationship, and psychological factors far more than by a single circulating hormone, and elevated androgens appear to interact with those other systems in a way that lowers rather than raises reported desire.

Is depression the real driver, more than the hormones?

In at least one direct comparison, yes — and by a wider margin than testosterone. A study of 106 women with PCOS and 106 matched controls found depression scores (BDI) were significantly higher and sexual function and sexual-quality-of-life scores significantly lower in the PCOS group, with a stronger negative correlation between depression and sexual function (r = -0.43) than has been reported for testosterone. Regression analysis identified depression as an independent predictor of impaired sexual quality of life, on top of and separate from the FSFI score itself (Mojahed et al., 2023). PCOS carries an elevated baseline rate of depression and anxiety independent of libido — covered fully in the prevalence data on PCOS, depression and anxiety — and that mood burden appears to explain a meaningful share of the reported drop in desire, separate from any hormone number on a lab report. Mood and desire aren’t the only PCOS symptoms with a hormone-sensitivity mechanism rather than a simple hormone-level one, either — the same theme shows up in why PMDD-type symptoms spike before a period some cycles don’t even produce, among the wider set of PCOS symptoms worth testing rather than assuming.

What is actually going on, mechanistically?

At least three separate pathways are competing for the “cause” here, and they aren’t mutually exclusive. First, androgen excess itself appears to disrupt normal desire regulation rather than enhance it, through mechanisms not yet fully mapped. Second, the physical symptoms of PCOS — hirsutism, acne, weight changes, and the body-image impact of all three — plausibly affect desire and satisfaction through a psychological route rather than a hormonal one; a 2019 study found body image concerns correlated with both anxiety, depression, and impaired sexual functioning in PCOS. Third, sexual pain and low lubrication are physical, not purely psychological, complaints, and the largest meta-analysis found the pain domain among the more consistently affected FSFI subscales (Bachega et al., 2025). Treating this as one problem with one hormonal fix ignores that at least three different mechanisms are plausibly stacking on top of each other.

Does the phenotype change the picture — insulin-resistant vs lean PCOS?

The published sexual-function studies generally don’t separate results by phenotype, which is itself worth naming rather than glossing over. What can be reasoned from adjacent evidence: the insulin-resistant pattern carries a higher combined burden of weight-related body-image concerns, sleep disruption, and metabolic symptoms that plausibly compound the psychological drivers of low desire described above, while lean PCOS — where androgen output and the LH-to-FSH imbalance tend to dominate over insulin resistance — sits closer to a pure test of the androgen-desire relationship, without the added weight-related variables. Neither pattern has been shown in a trial to protect against low libido, and no study yet reports sexual function outcomes broken down cleanly by phenotype, so this should be read as a reasoned hypothesis about mechanism, not a finding.

What doesn’t fix this, and who this isn’t about

Lowering testosterone is not a validated fix for low libido in PCOS, and the correlation data above is exactly why: if higher androgens tracked with lower function, an anti-androgen prescribed for acne or hirsutism — such as spironolactone — would be expected to improve libido as a side effect. No trial has demonstrated that reliably, and some antiandrogens carry the opposite reputation anecdotally. This also isn’t the right diagnosis for someone whose low desire is fully explained by a relationship factor, a medication side effect (hormonal contraceptives and SSRIs both commonly lower libido, independent of PCOS), or a straightforward reason like fatigue or stress — PCOS is one plausible contributor among several, not an automatic explanation for every case of low desire in someone who happens to have the diagnosis.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same condition, same hormone mechanisms — only the label changed. This article uses PCOS, since that is still the term most readers search.

Frequently asked questions

Your next step

Name the specific symptom to a clinician rather than the general label — “low desire since starting this medication” or “pain during sex for the last two months” gets investigated; “PCOS libido issues” often doesn’t, simply because it’s harder to act on.

That same directness carries over outside the clinic — how to tell a partner about PCOS covers naming a drop in desire without letting a partner draw the wrong conclusion about what it means.